Episode 97

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Featuring an interview with Prof Andreas Hochhaus, including the following topics:

  • Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
  • Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
  • Potential mechanisms of adverse events documented with TKIs (10:23)
  • Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
  • Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
  • Comparative efficacy of asciminib and other agents used to treat CML (40:01)
  • Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
  • Practical care strategies for CML patients; future developments (52:32)

CME information and select publications

All Episodes Previous Episode

About the Podcast

Show artwork for Hematologic Oncology Update
Hematologic Oncology Update
This series bridges the gap between research and patient care by providing medical oncologists with access to important information on relevant advances in the treatment of hematologic malignancies.

Listen for free